Charles Schwab Investment Management Inc. Grows Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Charles Schwab Investment Management Inc. increased its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 2.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 578,409 shares of the company's stock after acquiring an additional 12,906 shares during the period. Charles Schwab Investment Management Inc. owned about 0.97% of Protagonist Therapeutics worth $22,327,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. FNY Investment Advisers LLC bought a new stake in Protagonist Therapeutics in the 4th quarter worth about $38,000. Harvest Fund Management Co. Ltd bought a new stake in Protagonist Therapeutics in the 3rd quarter worth about $69,000. KBC Group NV grew its position in Protagonist Therapeutics by 54.4% in the 4th quarter. KBC Group NV now owns 2,093 shares of the company's stock worth $81,000 after purchasing an additional 737 shares in the last quarter. Nisa Investment Advisors LLC grew its position in Protagonist Therapeutics by 10.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company's stock worth $121,000 after purchasing an additional 295 shares in the last quarter. Finally, Caprock Group LLC bought a new stake in Protagonist Therapeutics in the 4th quarter worth about $224,000. Institutional investors and hedge funds own 98.63% of the company's stock.

Protagonist Therapeutics Price Performance

Shares of PTGX stock traded down $0.40 during mid-day trading on Friday, hitting $52.65. The company had a trading volume of 3,695,675 shares, compared to its average volume of 753,895. Protagonist Therapeutics, Inc. has a 52-week low of $24.22 and a 52-week high of $60.60. The stock's 50 day moving average price is $41.21 and its 200-day moving average price is $42.62. The company has a market capitalization of $3.23 billion, a P/E ratio of 19.79 and a beta of 2.34.

Remove Ads

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its quarterly earnings results on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $2.07. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. The company had revenue of $170.64 million for the quarter, compared to the consensus estimate of $56.65 million. On average, equities research analysts expect that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Insider Transactions at Protagonist Therapeutics

In other Protagonist Therapeutics news, CFO Asif Ali sold 24,903 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $58.73, for a total transaction of $1,462,553.19. Following the completion of the sale, the chief financial officer now directly owns 62,821 shares of the company's stock, valued at approximately $3,689,477.33. This represents a 28.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director William D. Waddill sold 4,000 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $54.25, for a total transaction of $217,000.00. Following the transaction, the director now directly owns 13,130 shares of the company's stock, valued at $712,302.50. This represents a 23.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 64,776 shares of company stock worth $3,585,010. Insiders own 5.40% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on PTGX. JPMorgan Chase & Co. upped their price objective on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 4th. JMP Securities reissued a "market outperform" rating and set a $58.00 target price on shares of Protagonist Therapeutics in a research report on Friday, February 7th. BTIG Research set a $73.00 target price on shares of Protagonist Therapeutics in a research report on Monday, March 3rd. Truist Financial increased their target price on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the company a "buy" rating in a research report on Tuesday, March 11th. Finally, BMO Capital Markets increased their target price on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the company an "outperform" rating in a research report on Tuesday, March 11th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Protagonist Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $62.56.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.